CN
DE
Contact Us
菜单
Telephone sharing button Contact Us linkedin sharing button Linked In wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Services
& Solutions

A global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics.

Technologies

Technology platforms that span the entire drug discovery to manufacturing spectrum.

WuXi XDC

A WuXi Biologics subsidiary, greatly simplifies bioconjugate development and manufacturing.

Mammalian

Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from concept to commercialization.

Testing

Providing extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories.

Microbial

 E. coli and yeast based expression systems, process development and cGMP manufacturing platform

Quality

World-class quality systems approved by the U.S. FDA, EMA and NMPA.

Viral

Viral vector based vaccine and therapeutic virus development and cGMP manufacturing platform.

Locations

Total estimated capacity for biopharmaceutical production in China, Ireland, the U.S., Germany and Singapore to exceed 580,000 liters by 2026.

United States
Massachusetts
U.S.
189,500sq. ft.
Operational2024
L‌earn M‌ore
New Jersey
U.S.
66,000sq. ft.
Operational2021
L‌earn M‌ore
Pennsylvania
U.S.
33,000sq. ft.
OperationalOctober. 2020
L‌earn M‌ore
Ireland
Dundalk
Ireland
26Hectare campus
Operational2022
L‌earn M‌ore
WuXi Vaccines
Ireland
$240Million investment
Operational2022
L‌earn M‌ore
Germany
Leverkusen
Germany
13,000+sq.m. facility
Operations2020
L‌earn M‌ore
Wuppertal
Germany
30,000+sq.m.
Operations2021
L‌earn M‌ore
Singapore
Singapore
$1.4Billion investment
OverTen Years
L‌earn M‌ore
China
Shanghai
Waigaoqiao Free Trade Zone
200,000 sq.ft
Opened April 2018
L‌earn M‌ore
Shanghai
Fengxian District
1.6 millionsq. ft.
Planned2021
L‌earn M‌ore
Wuxi
15,296sq.m.
OpenedOctober 2012
L‌earn M‌ore
Suzhou
16,000sq. m.
OpenedDecember 2014
L‌earn M‌ore
Hangzhou
30,000sq. m.
Operations2021
L‌earn M‌ore
Chengdu
314,000sq. m.
Planned2023
L‌earn M‌ore
Shijiazhuang
82,160sq. m.
Planned2022
L‌earn M‌ore
Hangzhou
50,000sq. m.
Operations2021
L‌earn M‌ore
Suzhou
11,500sq. m.
Operations2021
L‌earn M‌ore

Latest News

L‌earn M‌ore
Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?

Yes, continue to proceed
No, stay on this Website